Member Info for draft

Really hope the RTO is not done at a bad price if it ever happens

This probably will get the FDA approval as its an area of need now, and with the war and other economic issues, I dont think the FDA cant ''afford'' to let people down by not approving Tech like this, Do your own research, no advice intended

Easy 22p in my opinion, do your own research, no advice intended. this war aint over for years now

This is view of chatgpt, no advice intended, do your own research

Estimated Likelihood (My Reasoned Opinion)

Based on the evidence you provided:

Estimated FDA clearance probability

≈ 60–75%

Breakdown:

Clinical validity: ~85%

Analytical reproducibility: ~70%

Regulatory acceptance of PRS model: ~50–65%

Combined overall estimate:

➡️ ~65% likelihood of FDA clearance (assuming submission quality is strong).

3. Intellectual Property Protection

The genes, SNPs, and algorithms are patented in the US and EU.

While patents don’t affect FDA approval directly, they usually indicate:

Defined methodology

Novelty

Structured algorithm validation

4. Real-World Clinical Utility

The study examines incident coronary heart disease, not just genetic association.

This supports clinical utility, which the FDA increasingly wants for genomic tests.

Key Factors That Increase Approval Chances ✅

1. Large Clinical Validation Cohort

The test was evaluated in ~63,000 individuals over ~14 years in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort run by Kaiser Permanente Division of Research.

For diagnostics, this is very strong evidence because:

Most genetic diagnostic validations involve a few thousand patients

Longitudinal follow-up (14 years) strengthens predictive validity

➡️ This strongly supports clinical validity, which the FDA cares about.

2. Existing Regulatory Progress

The test already operates as an LDT (Laboratory Developed Test) in a Clinical Laboratory Improvement Amendments-certified lab.

It also received approval from the:

New York State Department of Health Clinical Laboratory Evaluation Program

This is important because New York has some of the strictest diagnostic review requirements in the U.S..

➡️ Passing NY review is often seen as a strong pre-validation step.

Lol do the opposite of what Goldman sachs say. always get it wrong

Not good

The government is preparing for a 'worst-case scenario' where the Middle East crisis continues to rage for months to come.

Internal analysis is said to have concluded oil prices could reach $150 a barrel if fighting continues until May, with gas costs also spiking.

Only a 'best case' presented to ministers, where the conflict ends within days, would see the price stabilising below $100 a barrel, according to Bloomberg.

Most people looking at oilies at the moment, but this should still get its rise in anticipation of FDA approval BUT it would be the first ever polygenic approval by the FDA according to chatgpt so this is a high bar here if they get the approval

This is perfectly placed away from the warzones

Really need this to be closer to 2p pre rto

Uk govt doesnt want the north sea so this will always suffer because of Labour

AI just searches for whatever is on the internet basically.

No where near the war so worth a punt, plus Oil in the name is bound to get a few punters jumping on the oil band wagon

also well below recent placing prices currently

Doenst look like this war will be over anytime soon

Could we see more blue today in expectation of rto?

Hmm so it does seem like it is FPP then, hmmm

Someone posted this on advfn , dunno if relevant here tbh

New pensions platform Freedom targets £330bn outflow bonanza

A new British fintech is targeting hundreds of billions of pounds in outflows from pension funds by striking a partnership with Visa which aims to give retirees greater control of their finances.

Sky News understands that Freedom, which will announce its launch this week, is raising £5m from investors to fund its expansion.

The company has recruited Charles McManus, one of Britain's leading fintech entrepreneurs and the founder of Clearbank, as its chairman.

As part of its launch, Freedom will say this week that Alltrust, the specialist SIPP provider with 11,000 members, has agreed to be the first pension provider to deploy its platform.

Badged as a Retirement-as-a-Service provider, Freedom's deal with Visa will see its regulated payments and card infrastructure embedded directly into pension schemes.

The new offering is designed to provide pensioners with bank-like access to their retirement income without the need for their scheme providers to become banks and without losing assets under management.

Freedom's development has been driven by the pressure on pension providers from retail banks for capital, with an estimated £330bn-£380 billion leaving the pension system and shifting to banks through a process known as decumulation.

This leakage of assets means that retirees forfeit long-term potential returns on their pension income, while pension providers lose assets under management.

Freedom is understood to be planning to launch with other major UK pension providers later in 2026.

“Banks are moving upstream into retirement through targeted support and embedded banking propositions," said Damian Stancombe, Freedom's chief executive.

"Pension providers must respond by moving downstream into access, liquidity and income.

“This phased rollout with Alltrust represents a strategic step toward embedding regulated banking and payments infrastructure directly within the pension environment, reducing asset leakage, strengthening retention and delivering modern retirement functionality without compromising governance.”

One pensions industry source described the launch as a "landmark" moment for an industry which remains characterised by a technology lag.

“The competitive landscape at retirement is changing," said James Floyd, managing director of Alltrust.

"Members expect the same simplicity and flexibility they experience in everyday banking, yet pension providers have historically lacked the infrastructure to deliver it within their product."

Freedom is expected to begin generating revenue imminently, and is targeting closing a roughly £5m capital-raising in the coming months.

“As people live longer and retirement becomes more flexible, expectations around access and usability continue to rise," said Olga Ovchinnikova, vice-president, business development at Visa UK & Ireland.

And no suspension